• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Nektar Therapeutics - Product Pipeline Review - 2012 Product Image

Nektar Therapeutics - Product Pipeline Review - 2012

  • ID: 2141813
  • May 2012
  • 92 pages
  • Global Markets Direct

Nektar Therapeutics – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Nektar Therapeutics - Product Pipeline Review - 2012” provides data on the Nektar Therapeutics’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Nektar Therapeutics’s corporate website, SEC filings, investor presentations and featured press releases, both from Nektar Therapeutics and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Nektar Therapeutics - Brief Nektar Therapeutics overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Nektar Therapeutics human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, READ MORE >



List of Tables
List of Figures
Nektar Therapeutics Snapshot
Nektar Therapeutics Overview
Key Information
Key Facts
Nektar Therapeutics – Research and Development Overview
Key Therapeutic Areas
Nektar Therapeutics – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Nektar Therapeutics – Pipeline Products Glance
Nektar Therapeutics – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Nektar Therapeutics Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Nektar Therapeutics – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Nektar Therapeutics – Drug Profiles
Longer Acting Therapeutic Clotting Proteins
Product Description
Mechanism of Action
R&D Progress
NKTR-063
Product Description
Mechanism of Action
R&D Progress
NKTR-102
Product Description
Mechanism of Action
R&D Progress
NKTR-102 + 5-Fluorouracil
Product Description
Mechanism of Action
R&D Progress
NKTR-105
Product Description
Mechanism of Action
R&D Progress
NKTR-125
Product Description
Mechanism of Action
R&D Progress
NKTR-140
Product Description
Mechanism of Action
R&D Progress
NKTR-171
Product Description
Mechanism of Action
R&D Progress
NKTR-181
Product Description
Mechanism of Action
R&D Progress
NKTR-192
Product Description
Mechanism of Action
R&D Progress
NKTR-194
Product Description
Mechanism of Action
R&D Progress
Nektar Therapeutics – Pipeline Analysis
Nektar Therapeutics – Pipeline Products by Therapeutic Class
Nektar Therapeutics – Pipeline Products By Target
Nektar Therapeutics – Pipeline Products by Route of Administration
Nektar Therapeutics – Pipeline Products By Mechanism of Action
Nektar Therapeutics – Recent Pipeline Updates
Nektar Therapeutics - Dormant Projects
Nektar Therapeutics - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
PEG-Alfacon
Nektar Therapeutics – Company Statement
Nektar Therapeutics – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Nektar Therapeutics, Recent Developments
Nektar Therapeutics- Press Release
Apr 02, 2012: Nektar Doses First Subjects In Phase I Clinical Study Evaluating NKTR-192 For Treatment Of Acute Pain
Feb 27, 2012: Nektar Presents Positive Phase I Clinical Data Of NKTR-181 At AAPM Annual Meeting
Oct 28, 2009: Nektar Completes Enrollment Ahead Of Schedule In Phase 2 Clinical Trial Evaluating NKTR-102 In Patients With Platinum-Resistant Ovarian Cancer
Sep 22, 2009: Nektar Reports NKTR-102 Shows Encouraging Anti-Tumor Activity In Ovarian Cancer In Phase I And Preclinical Data
Apr 22, 2009: Nektar's NKTR-105 Demonstrates Superior Antitumor Activity And Improved Pharmacokinetics Over Docetaxel In Preclinical Studies
Feb 17, 2009: Dosing Begins In Phase I Clinical Study Evaluating NKTR-105 In Cancer Patients With Refractory Solid Tumors
Jan 13, 2009: Nektar Therapeutics Announces Initiation Of First Patient Dosed In Phase 2 Clinical Trial Of NKTR-102 In Ovarian Cancer
Financial Deals Landscape
Nektar Therapeutics, Deals Summary
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Pearl Therapeutics Secures Additional $18 Million In Series A Financing
Private Equity
Aerogen Completes Management Buyout
Partnerships
Nektar Therapeutics Enters Into Co-Development Agreement With Baxter International
Nektar Therapeutics Enters Into Co-Development Agreement With Bayer HealthCare
Nektar Therapeutics Signs Co-Development Agreement With Bayer HealthCare
Nektar Therapeutics Enters Into Co-Development Agreement With Baxter International
Nektar Therapeutics Enters Into An Agreement With Bayer HealthCare
Nektar Therapeutics Enters Into Co-Development Agreement With Zelos Therapeutics
Respironics Enters Into Co-Marketing Agreement With Nektar Therapeutics
SciClone Pharma Enters Into Co-Development Agreement With Nektar Therapeutics
Licensing Agreements
Nektar Therapeutics Enters Into Licensing Agreement With GlaxoSmithKline
Nektar Therapeutics Enters Into Licensing Agreement With AstraZeneca
Nektar Therapeutics Enters Into Licensing Agreement With Pfizer
Nektar Therapeutics Enters Into Licensing Agreement With MAP Pharma
Nektar Therapeutics Enters Into Licensing Agreement With Affymax
Nektar Therapeutics Enters Into Licensing Agreement With Roche
Equity Offering
Nektar Therapeutics Completes Underwritten Public Offering Of Its Common Stock For $225 Million
Nektar Therapeutics Completes Private Placement Of $8 Million
Nektar Therapeutics Completes Private Placement Of $24 Million
Nektar Therapeutics Completes Public Offering Of $197 Million
Debt Offering
Nektar Therapeutics Completes Private Placement Of 3.25% Convertible Subordinated Notes For $315 Million
Asset Transactions
Nektar Therapeutics To Sell Royalty Of CIMZIA and MIRCERA To RPI Finance Trust For $124 Million
Novartis Acquires Pulmonary Drug-Delivery Business Unit Of Nektar Therapeutics
Acquisition
Nektar Therapeutics Acquires Aerogen
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Nektar Therapeutics, Key Information
Nektar Therapeutics, Key Facts
Nektar Therapeutics – Pipeline by Indication, 2012
Nektar Therapeutics – Pipeline by Stage of Development, 2012
Nektar Therapeutics – Monotherapy Products in Pipeline, 2012
Nektar Therapeutics – Combination Treatment Modalities in Pipeline, 2012
Nektar Therapeutics – Phase III, 2012
Nektar Therapeutics – Phase II, 2012
Nektar Therapeutics – Phase I, 2012
Nektar Therapeutics – Pre-Clinical, 2012
Nektar Therapeutics – Discovery, 2012
Nektar Therapeutics – Pipeline By Therapeutic Class, 2012
Nektar Therapeutics - Pipeline By Target, 2012
Nektar Therapeutics – Pipeline By Route of Administration, 2012
Nektar Therapeutics – Pipeline Products By Mechanism of Action, 2012
Nektar Therapeutics – Recent Pipeline Updates, 2012
Nektar Therapeutics - Dormant Developmental Projects,2012
Nektar Therapeutics - Discontinued Pipeline Products, 2012
Nektar Therapeutics, Other Locations
Nektar Therapeutics, Subsidiaries
Nektar Therapeutics, Deals Summary
Pearl Therapeutics Secures Additional $18 Million In Series A Financing
Aerogen Completes Management Buyout
Nektar Therapeutics Enters Into Co-Development Agreement With Baxter International
Nektar Therapeutics Enters Into Co-Development Agreement With Bayer HealthCare
Nektar Therapeutics Signs Co-Development Agreement With Bayer HealthCare
Nektar Therapeutics Enters Into Co-Development Agreement With Baxter International
Nektar Therapeutics Enters Into An Agreement With Bayer HealthCare
Nektar Therapeutics Enters Into Co-Development Agreement With Zelos Therapeutics
Respironics Enters Into Co-Marketing Agreement With Nektar Therapeutics
SciClone Pharma Enters Into Co-Development Agreement With Nektar Therapeutics
Nektar Therapeutics Enters Into Licensing Agreement With GlaxoSmithKline
Nektar Therapeutics Enters Into Licensing Agreement With AstraZeneca
Nektar Therapeutics Enters Into Licensing Agreement With Pfizer
Nektar Therapeutics Enters Into Licensing Agreement With MAP Pharma
Nektar Therapeutics Enters Into Licensing Agreement With Affymax
Nektar Therapeutics Enters Into Licensing Agreement With Roche
Nektar Therapeutics Completes Underwritten Public Offering Of Its Common Stock For $225 Million
Nektar Therapeutics Completes Private Placement Of $8 Million
Nektar Therapeutics Completes Private Placement Of $24 Million
Nektar Therapeutics Completes Public Offering Of $197 Million
Nektar Therapeutics Completes Private Placement Of 3.25% Convertible Subordinated Notes For $315 Million
Nektar Therapeutics To Sell Royalty Of CIMZIA and MIRCERA To RPI Finance Trust For $124 Million
Novartis Acquires Pulmonary Drug-Delivery Business Unit Of Nektar Therapeutics
Nektar Therapeutics Acquires Aerogen

List of Figures
Nektar Therapeutics – Pipeline by Indication, 2012
Nektar Therapeutics – Pipeline by Stage of Development, 2012
Nektar Therapeutics – Monotherapy Products in Pipeline, 2012
Nektar Therapeutics – Combination Treatment Modalities in Pipeline, 2012
Nektar Therapeutics – Pipeline By Therapeutic Class, 2012
Nektar Therapeutics – Pipeline By Route of Administration, 2012
Nektar Therapeutics - Pipeline Products By Mechanism of Action, 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos